We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Supports Pembrolizumab for High-Risk Invasive Bladder Cancer
FDA Advisory Committee Supports Pembrolizumab for High-Risk Invasive Bladder Cancer
The FDA’s Oncologic Drugs Advisory Committee voted 9-4 yesterday to recommend approval of Merck’s Keytruda (pembrolizumab) injection for treatment of certain patients with bladder cancer who are ineligible for surgery or have opted out.